GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. (WGS) is a leader in "Precision Medicine," specializing in exome and genome testing for rare diseases and pediatrics. Led by CEO Katherine Stueland, GeneDx’s mission is to "Deliver health intelligence that improves outcomes." The company holds a dominant industry position, owning the world’s largest dataset of rare disease clinical exomes. By late 2025, WGS stock has been a "Hyper-Growth Star," reporting 52% year-over-year revenue growth and achieving its fourth consecutive profitable quarter in Q3 2025. Its vision is to make whole genome sequencing the standard of care for every child with a suspected genetic condition.

The business operations of GeneDx are powered by its "Infinity™" platform, which automates the interpretation of complex genetic data. The core growth driver in 2025 has been "The Exome-First Pivot," with exome and genome revenue growing 65% year-over-year. In late 2025, WGS raised its full-year revenue guidance to $425M–$428M and expanded its adjusted gross margin to a record 74%. The 2026 strategic roadmap focuses on "The FDA Breakthrough Expansion," aiming to leverage its newly granted Breakthrough Device Designation for its ExomeDx and GenomeDx tests to secure broader insurance coverage. By utilizing its "Data Moat"—which allows it to identify disease-causing variants with higher accuracy than any competitor—GeneDx maintains a significant clinical edge. This "Diagnostic Superiority" is a primary driver for the WGS stock price. The company’s acquisition of Fabric Genomics in 2025 has also accelerated its AI interpretation capabilities, providing a tech-moat for WGS stock holders.